IBSA continues to invest in Research, by developing innovative products in the osteoarticular area
25 November 2021
In the current historical period – disrupted by the global pandemic – health issues, the well-being of the entire community and the role of the pharmaceutical sector have become increasingly important on the agenda of institutions, investors, consultants and managers. The health and well-being of the People are a topic to be addressed, in Italy as well as worldwide, and the sector is driven not only by vaccines, but also by the development of innovative products in other therapeutic areas.
IBSA Farmaceutici too is concretely contributing to supporting the Health System, by continuing to invest in research and innovation in order to offer therapeutic solutions capable of addressing the needs of patients. Active in 10 therapeutic areas – and with a particular focus in Endocrinology and Reproductive Medicine and in the Osteoarticular and Aesthetic Medicine area – IBSA Farmaceutici launches new products that will enrich its therapeutic offer.
IBSA - one of the world leaders in the production and development of hyaluronic acid-based products - manages the entire supply chain, from the biotechnological production of hyaluronate up to the manufacture of finished products, such as pre-filled syringe vials for intra-articular infiltration.
“In this context”, reports Andrea Giori, Head of Research & Development, “we developed a new formulation of hyaluronic acid and chondroitin, both obtained through bio-fermentation, through IBSA patented processes, and therefore safer for the intra-articular use than those of animal extraction".
The development of the new medical device was made possible thanks to the collaboration between our Research and Development department and several Italian clinical and research centres, including the Biomedical Campus of Rome, the San Raffaele in Milan and the University "Luigi Vanvitelli" of Campania”.
Sodium chondroitin is combined with hyaluronic acid through the NAHYCO® TECHNOLOGY, a patented thermal process that allows the formation of weak bonds between the two components with different molecular weight, to form hybrid molecular complexes. The use of biotechnological ingredients and the absence of chemical modifications allows to ensure an optimal safety profile.